News from the FDA/CDC

FDA approves first RSV vaccine for older adults


 

The U.S. Food and Drug Administration (FDA) has approved the first vaccine for respiratory syncytial virus (RSV) in the United States, the agency announced May 3. Arexvy, manufactured by GSK, is the world’s first RSV vaccine for adults aged 60 years and older, the company said in an announcement.

Every year, RSV is responsible for 60,000–120,000 hospitalizations and 6,000–10,000 deaths among U.S. adults older than age, according to the FDA. Older adults with underlying health conditions — such as diabetes, a weakened immune system, or lung or heart disease — are at high risk for severe disease. "Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States," said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, in a statement.

The FDA approval of Arexvy was based on a clinical study of approximately 25,000 patients. Half of these patients received Arexvy, while the other half received a placebo. Researchers found that the RSV vaccine reduced RSV-associated lower respiratory tract disease (LRTD) by nearly 83% and reduced the risk of developing severe RSV-associated LRTD by 94%. The most commonly reported side effects were injection site pain, fatigue, muscle pain, headache, and joint stiffness/pain. Ten patients who received Arexvy and four patients who received placebo experienced atrial fibrillation within 30 days of vaccination. The company is planning to assess risk for atrial fibrillation in postmarking studies, the FDA said. The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended approval of Arexvy on April 25, 2023, on the basis of data from the same clinical trial.

GSK said that the U.S. launch of Arexvy will occur sometime in the fall before the 2023/2024 RSV season, but the company did not provide exact dates. "Today marks a turning point in our effort to reduce the significant burden of RSV," said GSK’s chief scientific officer, Tony Wood, PhD, in a company statement. "Our focus now is to ensure eligible older adults in the U.S. can access the vaccine as quickly as possible and to progress regulatory review in other countries."

A version of this article first appeared on Medscape.com.

Recommended Reading

Physicians and clinicians should be required to get flu shots: Ethicist
Journal of Clinical Outcomes Management
One in four parents lied about kids’ COVID status: Survey
Journal of Clinical Outcomes Management
Measles exposures in Kentucky have CDC on alert
Journal of Clinical Outcomes Management
Factors linked with increased VTE risk in COVID outpatients
Journal of Clinical Outcomes Management
NOVIDs: Do some have the genes to dodge COVID?
Journal of Clinical Outcomes Management
COVID-19 vaccinations lag in youngest children
Journal of Clinical Outcomes Management
Nasal COVID treatment shows early promise against multiple variants
Journal of Clinical Outcomes Management
Parents of patients with rheumatic disease, MIS-C strongly hesitant of COVID vaccination
Journal of Clinical Outcomes Management
CDC backs FDA’s call for second COVID booster for those at high risk
Journal of Clinical Outcomes Management
‘Exciting’ results for cancer vaccine plus pembro in melanoma
Journal of Clinical Outcomes Management